News Column

New Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients

August 18, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101 (see also Can-Fite BioPharma Ltd.).

The retrospective study, conducted by a third party statistician group, analyzed the correlation between response to CF101 and patients' body mass index (BMI) in the Phase II/III Psoriasis interim results as well as the recently completed Phase II Rheumatoid Arthritis trial. The data shows a significant increase in the response to CF101 in patients with a BMI of over 25 in both studies. These findings corroborate the efficacy seen with other FDA approved drugs such as Cyclosporine A which was more effective in patients with high BMI. The company believes these findings will enable it to optimize the design of its forthcoming Phase III studies.

"These new findings are further evidence of CF101's high efficacy, while the drug continues to show excellent safety in patients. We believe the data will be very important to the design of our forthcoming Phase III trials because these findings help us to achieve the maximum potential of the drug in the treatment of inflammatory conditions," stated Can-Fite CEO Pnina Fishman.

Can-Fite's Phase II/III Psoriasis trial is ongoing with data expected to be released in the first quarter of 2015. The Psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data. The market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects.

The global Rheumatoid Arthritis drug market is expected to generate revenues of $38.5 billion in 2017, according to Visiongain.

Keywords for this news article include: Drugs, Therapy, Psoriasis, Dermatology, Joint Diseases, Biopharmaceuticals, Rheumatoid Arthritis, Can-Fite BioPharma Ltd., Musculoskeletal Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters